Trial Profile
Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)-An Extension Study of Eltrombopag in Subjects, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study TRA108109 (NCT00540423)-<Phase III Study>
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 28 Sep 2015 New trial record